A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes - PIONEER6 - Cardiovascular outcomes

ovo Nordisk0 个研究点目标入组 75 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•-Male or female diagnosed with type 2 diabetes (T2D)
•-Age * 50 years at screening and presence of cardiovascular disease, or age * 60 years at screening and presence of at least one cardiovascular risk factor

•-Current or previous (within 90 days prior to screening) treatment with any GLP-1 receptor agonist, DPP-4 inhibitor or pramlintide
•-Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC)
•-History of pancreatitis (acute or chronic)
•-History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)
•-Subjects presently classified as being in New York Heart Association (NYHA) Class IV heart failure
•-Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
•-Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 60 days prior to screening
•-Chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment (corresponding to eGFR <30 mL/min/1.73 m2)
•-History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)
•-Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus
•photography or dilated fundoscopy performed within 90 days prior to screening or within the
•period between screening and randomisation.

发起方

ovo Nordisk